Home
Drugs
Carboplatin
Clinical Trials

Clinical Trials Related to Carboplatin

Related studies linked through entity extraction aliases.

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

Status: RECRUITING
Phase: PHASE3

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

Status: RECRUITING
Phase: PHASE2

A Study of LY4175408 in Participants With Advanced Cancer

Status: RECRUITING
Phase: PHASE1

Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery

Status: NOT_YET_RECRUITING
Phase: PHASE2

Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial Carcinoma

Status: RECRUITING
Phase: PHASE2

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

Status: RECRUITING
Phase: PHASE2

Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%

Status: RECRUITING
Phase: PHASE2

A Study of SKB518 in Patients With Lung Cancer

Status: RECRUITING
Phase: PHASE2

Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer

Status: RECRUITING
Phase: PHASE2

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

Status: RECRUITING
Phase: PHASE2

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

Status: RECRUITING
Phase: PHASE3

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Status: RECRUITING
Phase: PHASE2/PHASE3

INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma

Status: RECRUITING
Phase: PHASE3

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

Status: RECRUITING
Phase: PHASE1/PHASE2

SHR - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer

Status: NOT_YET_RECRUITING
Phase: PHASE1/PHASE2

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

Status: RECRUITING
Phase: PHASE3

A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC

Status: RECRUITING
Phase: PHASE1

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Status: RECRUITING
Phase: PHASE3

Stromal Tumor-Infiltrating Lymphocyte Levels Are Associated With Immune Checkpoint Proteins In Triple Negative Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

Status: COMPLETED
Phase: N/A

A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)

Status: TERMINATED
Phase: PHASE2